Venetoclax-阿扎胞苷桥接 PTCy-haplo-PBSCT 治疗 IDH2 突变的难治性急性髓系白血病。
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations.
发表日期：2023
作者：
Yusuke Daido, Hiroyuki Sugiura, Tatsunori Ishikawa, Taiga Kuroi, Sachiyo Okamoto, Naho Nomura, Taro Masunari, Nobuo Sezaki, Yasuhito Nannya, Seishi Ogawa, Mitsune Tanimoto
来源：
Stem Cell Research & Therapy
摘要：
Venetoclax 和阿扎胞苷联合疗法 (VEN AZA) 是治疗老年或身体不适的急性髓系白血病 (AML) 患者的一种有前景的新型疗法。最近，有报道称VEN AZA随后进行同种异体造血干细胞移植，而使用来自相关供者的移植后环磷酰胺（PTCy-haplo-PBSCT）进行人白细胞抗原半相合外周血干细胞移植似乎是一个合适的选择。在此，我们报告了两名携带 IDH2 突变的难治性 AML 老年患者，他们成功接受了 VEN AZA 桥接到 PTCy-haplo-PBSCT 的治疗。本报告表明 VEN AZA 作为难治性 AML 中 PTCy-haplo-PBSCT 的桥接治疗的有效性和安全性。© 2023 作者。由巴塞尔 S. Karger AG 出版。
Venetoclax and azacitidine combination therapy (VEN+AZA) is a promising novel therapy for elderly or unfit patients with acute myeloid leukemia (AML). Recently, VEN+AZA with subsequent allo-hematopoietic stem cell transplantation has been reported, and human leukocyte antigen-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haplo-PBSCT) from related donors appears to be a suitable option. Here, we report two elderly patients with refractory AML harboring an IDH2 mutation, who were successfully treated with VEN+AZA bridged to PTCy-haplo-PBSCT. This report suggests the efficacy and safety of VEN+AZA as a bridging treatment for PTCy-haplo-PBSCT in refractory AML.© 2023 The Author(s). Published by S. Karger AG, Basel.